Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 26 entries
Sorted by: Best Match Show Resources per page
Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression.

Bladder cancer (Amsterdam, Netherlands)

Godoy G, Gakis G, Smith CL, Fahmy O.
PMID: 27376135
Bladder Cancer. 2016 Apr 27;2(2):127-137. doi: 10.3233/BLC-160052.

Epidemiologic studies have long demonstrated clear differences in incidence and progression of bladder cancer between genders suggesting that the mechanisms of development and progression in these tumors have a strong association with steroid hormonal pathways. Such observations led to...

Cite
Godoy G, Gakis G, Smith CL, et al. Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder Cancer. 2016;2(2):127-137doi: 10.3233/BLC-160052.
Godoy, G., Gakis, G., Smith, C. L., & Fahmy, O. (2016). Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder cancer (Amsterdam, Netherlands), 2(2), 127-137. https://doi.org/10.3233/BLC-160052
Godoy, Guilherme, et al. "Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression." Bladder cancer (Amsterdam, Netherlands) vol. 2,2 (2016): 127-137. doi: https://doi.org/10.3233/BLC-160052
Godoy G, Gakis G, Smith CL, Fahmy O. Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder Cancer. 2016 Apr 27;2(2):127-137. doi: 10.3233/BLC-160052. PMID: 27376135; PMCID: PMC4927898.
Copy Download .nbib Format: NLM
Androgen deprivation therapy for prostate cancer-review of indications in 2010.

Current oncology (Toronto, Ont.)

Quon H, Loblaw DA.
PMID: 20882131
Curr Oncol. 2010 Sep;17:S38-44. doi: 10.3747/co.v17i0.698.

The discovery of androgen deprivation therapy (ADT) has been one of the most important advances in the treatment of prostate cancer. Here, the indications for the use of ADT are reviewed, together with the data supporting each indication. The...

Cite
Quon H, Loblaw DA. Androgen deprivation therapy for prostate cancer-review of indications in 2010. Curr Oncol. 2010;17:S38-44doi: 10.3747/co.v17i0.698.
Quon, H., & Loblaw, D. A. (2010). Androgen deprivation therapy for prostate cancer-review of indications in 2010. Current oncology (Toronto, Ont.), 17S38-44. https://doi.org/10.3747/co.v17i0.698
Quon, H, and Loblaw, D A. "Androgen deprivation therapy for prostate cancer-review of indications in 2010." Current oncology (Toronto, Ont.) vol. 17 (2010): S38-44. doi: https://doi.org/10.3747/co.v17i0.698
Quon H, Loblaw DA. Androgen deprivation therapy for prostate cancer-review of indications in 2010. Curr Oncol. 2010 Sep;17:S38-44. doi: 10.3747/co.v17i0.698. PMID: 20882131; PMCID: PMC2935708.
Copy Download .nbib Format: NLM
Identifying 5 Common Psychiatric Disorders Associated Chemicals Through Integrative Analysis of Genome-Wide Association Study and Chemical-Gene Interaction Datasets.

Schizophrenia bulletin

Cheng S, Wen Y, Ma M, Zhang L, Liu L, Qi X, Cheng B, Liang C, Li P, Kafle OP, Zhang F.
PMID: 32291453
Schizophr Bull. 2020 Apr 15; doi: 10.1093/schbul/sbaa053. Epub 2020 Apr 15.

Psychiatric disorders are a group of complex psychological syndromes whose etiology remains unknown. Previous study suggested that various chemicals contributed to the development of psychiatric diseases through affecting gene expression. This study aims to systematically explore the potential relationships...

Cite
Cheng S, Wen Y, Ma M, et al. Identifying 5 Common Psychiatric Disorders Associated Chemicals Through Integrative Analysis of Genome-Wide Association Study and Chemical-Gene Interaction Datasets. Schizophr Bull. 2020;doi: 10.1093/schbul/sbaa053.
Cheng, S., Wen, Y., Ma, M., Zhang, L., Liu, L., Qi, X., Cheng, B., Liang, C., Li, P., Kafle, O. P., & Zhang, F. (2020). Identifying 5 Common Psychiatric Disorders Associated Chemicals Through Integrative Analysis of Genome-Wide Association Study and Chemical-Gene Interaction Datasets. Schizophrenia bulletin, . https://doi.org/10.1093/schbul/sbaa053
Cheng, Shiqiang, et al. "Identifying 5 Common Psychiatric Disorders Associated Chemicals Through Integrative Analysis of Genome-Wide Association Study and Chemical-Gene Interaction Datasets." Schizophrenia bulletin vol. (2020). doi: https://doi.org/10.1093/schbul/sbaa053
Cheng S, Wen Y, Ma M, Zhang L, Liu L, Qi X, Cheng B, Liang C, Li P, Kafle OP, Zhang F. Identifying 5 Common Psychiatric Disorders Associated Chemicals Through Integrative Analysis of Genome-Wide Association Study and Chemical-Gene Interaction Datasets. Schizophr Bull. 2020 Apr 15; doi: 10.1093/schbul/sbaa053. Epub 2020 Apr 15. PMID: 32291453; PMCID: PMC7505178.
Copy Download .nbib Format: NLM
Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy.

The world journal of men's health

Casado E, Borque-Fernando A, Caamaño M, Graña J, Muñoz-Rodríguez J, Morote J.
PMID: 34983087
World J Mens Health. 2022 Jan;40(1):74-86. doi: 10.5534/wjmh.210061.

Patients with prostate cancer (PCa) on androgen-deprivation therapy (ADT) are at high risk of osteoporosis and fragility fractures. We aimed to provide some practical insights into the delivery of optimal bone health care for PCa patients, particularly those on...

Cite
Casado E, Borque-Fernando A, Caamaño M, et al. Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy. World J Mens Health. 2022;40(1):74-86doi: 10.5534/wjmh.210061.
Casado, E., Borque-Fernando, A., Caamaño, M., Graña, J., Muñoz-Rodríguez, J., & Morote, J. (2022). Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy. The world journal of men's health, 40(1), 74-86. https://doi.org/10.5534/wjmh.210061
Casado, Enrique, et al. "Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy." The world journal of men's health vol. 40,1 (2022): 74-86. doi: https://doi.org/10.5534/wjmh.210061
Casado E, Borque-Fernando A, Caamaño M, Graña J, Muñoz-Rodríguez J, Morote J. Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy. World J Mens Health. 2022 Jan;40(1):74-86. doi: 10.5534/wjmh.210061. PMID: 34983087.
Copy Download .nbib Format: NLM
The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications.

Indian journal of urology : IJU : journal of the Urological Society of India

Ramos JA, Bianco FJ.
PMID: 22557710
Indian J Urol. 2012 Jan;28(1):9-14. doi: 10.4103/0970-1591.94942.

Prostate cancer is a global public health problem, and it is the most common cancer in American men and the second cause for cancer-related death. Experimental evidence shows that prostate tissue possesses cannabinoid receptors and their stimulation results in...

Cite
Ramos JA, Bianco FJ. The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. Indian J Urol. 2012;28(1):9-14doi: 10.4103/0970-1591.94942.
Ramos, J. A., & Bianco, F. J. (2012). The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. Indian journal of urology : IJU : journal of the Urological Society of India, 28(1), 9-14. https://doi.org/10.4103/0970-1591.94942
Ramos, Juan A, and Bianco, Fernando J. "The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications." Indian journal of urology : IJU : journal of the Urological Society of India vol. 28,1 (2012): 9-14. doi: https://doi.org/10.4103/0970-1591.94942
Ramos JA, Bianco FJ. The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. Indian J Urol. 2012 Jan;28(1):9-14. doi: 10.4103/0970-1591.94942. PMID: 22557710; PMCID: PMC3339795.
Copy Download .nbib Format: NLM
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.

European urology

Saad F, Small EJ, Feng FY, Graff JN, Olmos D, Hadaschik BA, Oudard S, Londhe A, Bhaumik A, Lopez-Gitlitz A, Thomas S, Mundle SD, Chowdhury S, Smith MR.
PMID: 34916086
Eur Urol. 2021 Dec 13; doi: 10.1016/j.eururo.2021.11.020. Epub 2021 Dec 13.

BACKGROUND: Apalutamide plus androgen deprivation therapy (ADT) significantly improved metastasis-free survival (MFS), overall survival (OS), and time to prostate-specific antigen (PSA) progression in the placebo-controlled SPARTAN study of high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).OBJECTIVE: To assess the relationships between...

Cite
Saad F, Small EJ, Feng FY, et al. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. Eur Urol. 2021;doi: 10.1016/j.eururo.2021.11.020.
Saad, F., Small, E. J., Feng, F. Y., Graff, J. N., Olmos, D., Hadaschik, B. A., Oudard, S., Londhe, A., Bhaumik, A., Lopez-Gitlitz, A., Thomas, S., Mundle, S. D., Chowdhury, S., & Smith, M. R. (2021). Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. European urology, . https://doi.org/10.1016/j.eururo.2021.11.020
Saad, Fred, et al. "Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN." European urology vol. (2021). doi: https://doi.org/10.1016/j.eururo.2021.11.020
Saad F, Small EJ, Feng FY, Graff JN, Olmos D, Hadaschik BA, Oudard S, Londhe A, Bhaumik A, Lopez-Gitlitz A, Thomas S, Mundle SD, Chowdhury S, Smith MR. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. Eur Urol. 2021 Dec 13; doi: 10.1016/j.eururo.2021.11.020. Epub 2021 Dec 13. PMID: 34916086.
Copy Download .nbib Format: NLM
Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis.

Infectious agents and cancer

Duarte MBO, Leal F, Argenton JLP, Carvalheira JBC.
PMID: 34823563
Infect Agent Cancer. 2021 Nov 25;16(1):66. doi: 10.1186/s13027-021-00406-y.

BACKGROUND: Previous studies hypothesized that androgen deprivation therapy (ADT) may reduce severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infectivity. However, it is unknown whether there is an association between ADT and a higher survival in prostate cancer patients with...

Cite
Duarte MBO, Leal F, Argenton JLP, et al. Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis. Infect Agent Cancer. 2021;16(1):66doi: 10.1186/s13027-021-00406-y.
Duarte, M. B. O., Leal, F., Argenton, J. L. P., & Carvalheira, J. B. C. (2021). Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis. Infectious agents and cancer, 16(1), 66. https://doi.org/10.1186/s13027-021-00406-y
Duarte, Mateus Bringel Oliveira, et al. "Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis." Infectious agents and cancer vol. 16,1 (2021): 66. doi: https://doi.org/10.1186/s13027-021-00406-y
Duarte MBO, Leal F, Argenton JLP, Carvalheira JBC. Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis. Infect Agent Cancer. 2021 Nov 25;16(1):66. doi: 10.1186/s13027-021-00406-y. PMID: 34823563; PMCID: PMC8614632.
Copy Download .nbib Format: NLM
Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer.

IJU case reports

Kohada Y, Kaiho Y, Takeda K, Kuromoto A, Ito J, Teishima J, Nakamura Y, Kaifu T, Nakamura A, Sato M.
PMID: 34755058
IJU Case Rep. 2021 Aug 01;4(6):367-370. doi: 10.1002/iju5.12351. eCollection 2021 Nov.

INTRODUCTION: The present study showed the involvement of immunosuppressive myeloid-derived suppressor cells during the disease progression in a 69-year-old man with a prostate cancer.CASE PRESENTATION: The patient with metastatic PC (cT4N1M1ab) was initially treated with primary androgen deprivation therapy...

Cite
Kohada Y, Kaiho Y, Takeda K, et al. Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer. IJU Case Rep. 2021;4(6):367-370doi: 10.1002/iju5.12351.
Kohada, Y., Kaiho, Y., Takeda, K., Kuromoto, A., Ito, J., Teishima, J., Nakamura, Y., Kaifu, T., Nakamura, A., & Sato, M. (2021). Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer. IJU case reports, 4(6), 367-370. https://doi.org/10.1002/iju5.12351
Kohada, Yuki, et al. "Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer." IJU case reports vol. 4,6 (2021): 367-370. doi: https://doi.org/10.1002/iju5.12351
Kohada Y, Kaiho Y, Takeda K, Kuromoto A, Ito J, Teishima J, Nakamura Y, Kaifu T, Nakamura A, Sato M. Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer. IJU Case Rep. 2021 Aug 01;4(6):367-370. doi: 10.1002/iju5.12351. eCollection 2021 Nov. PMID: 34755058; PMCID: PMC8560438.
Copy Download .nbib Format: NLM
Current treatment of non-metastatic castration-refractory prostate cancer.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Büchler T.
PMID: 34362254
Klin Onkol. 2021;34(3):185-191. doi: 10.48095/ccko2021185.

BACKGROUND: Non-metastatic castration-refractory prostate cancer (nmCRPC) is defined by increasing serum prostate specific antigen (PSA) levels despite androgen deprivation therapy in the absence of metastases on standard imaging methods including CT of the chest, abdomen and pelvis, and bone...

Cite
Büchler T. Léčba nemetastatického kastračně refrakterního karcinomu prostaty. Current treatment of non-metastatic castration-refractory prostate cancer. Klin Onkol. 2021;34(3):185-191doi: 10.48095/ccko2021185.
Büchler, T. (2021). Léčba nemetastatického kastračně refrakterního karcinomu prostaty. Current treatment of non-metastatic castration-refractory prostate cancer. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 34(3), 185-191. https://doi.org/10.48095/ccko2021185
Büchler, Tomáš. "Léčba nemetastatického kastračně refrakterního karcinomu prostaty." Current treatment of non-metastatic castration-refractory prostate cancer. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti vol. 34,3 (2021): 185-191. doi: https://doi.org/10.48095/ccko2021185
Büchler T. Léčba nemetastatického kastračně refrakterního karcinomu prostaty. Current treatment of non-metastatic castration-refractory prostate cancer. Klin Onkol. 2021;34(3):185-191. doi: 10.48095/ccko2021185. PMID: 34362254.
Copy Download .nbib Format: NLM
Androgenic Activity of Antiandrogens Predicted by Fit into DNA.

American journal of therapeutics

Steinsapir J, Mora G, Muldoon TG, Mahesh VB, Hendry LB.
PMID: 11835093
Am J Ther. 1994 Oct;1(3):236-244. doi: 10.1097/00045391-199410000-00011.

Computer modeling including graphics and energy calculations were employed for the first time to examine the stereochemical fit of antiandrogens into double-stranded DNA. In this study, we assessed the relative fit of antiandrogens in the cavity between base pairs...

Cite
Steinsapir J, Mora G, Muldoon TG, et al. Androgenic Activity of Antiandrogens Predicted by Fit into DNA. Am J Ther. 1994;1(3):236-244doi: 10.1097/00045391-199410000-00011.
Steinsapir, J., Mora, G., Muldoon, T. G., Mahesh, V. B., & Hendry, L. B. (1994). Androgenic Activity of Antiandrogens Predicted by Fit into DNA. American journal of therapeutics, 1(3), 236-244. https://doi.org/10.1097/00045391-199410000-00011
Steinsapir, Jaime, et al. "Androgenic Activity of Antiandrogens Predicted by Fit into DNA." American journal of therapeutics vol. 1,3 (1994): 236-244. doi: https://doi.org/10.1097/00045391-199410000-00011
Steinsapir J, Mora G, Muldoon TG, Mahesh VB, Hendry LB. Androgenic Activity of Antiandrogens Predicted by Fit into DNA. Am J Ther. 1994 Oct;1(3):236-244. doi: 10.1097/00045391-199410000-00011. PMID: 11835093.
Copy Download .nbib Format: NLM
Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making.

Environmental health perspectives

Woodruff TJ, Zeise L, Axelrad DA, Guyton KZ, Janssen S, Miller M, Miller GG, Schwartz JM, Alexeeff G, Anderson H, Birnbaum L, Bois F, Cogliano VJ, Crofton K, Euling SY, Foster PM, Germolec DR, Gray E, Hattis DB, Kyle AD, Luebke RW, Luster MI, Portier C, Rice DC, Solomon G, Vandenberg J, Zoeller RT.
PMID: 19057713
Environ Health Perspect. 2008 Nov;116(11):1568-75. doi: 10.1289/ehp.11516. Epub 2008 Jul 10.

BACKGROUND: Assessing adverse effects from environmental chemical exposure is integral to public health policies. Toxicology assays identifying early biological changes from chemical exposure are increasing our ability to evaluate links between early biological disturbances and subsequent overt downstream effects....

Cite
Woodruff TJ, Zeise L, Axelrad DA, et al. Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making. Environ Health Perspect. 2008;116(11):1568-75doi: 10.1289/ehp.11516.
Woodruff, T. J., Zeise, L., Axelrad, D. A., Guyton, K. Z., Janssen, S., Miller, M., Miller, G. G., Schwartz, J. M., Alexeeff, G., Anderson, H., Birnbaum, L., Bois, F., Cogliano, V. J., Crofton, K., Euling, S. Y., Foster, P. M., Germolec, D. R., Gray, E., Hattis, D. B., Kyle, A. D., Luebke, R. W., Luster, M. I., Portier, C., Rice, D. C., Solomon, G., Vandenberg, J., & Zoeller, R. T. (2008). Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making. Environmental health perspectives, 116(11), 1568-75. https://doi.org/10.1289/ehp.11516
Woodruff, Tracey J, et al. "Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making." Environmental health perspectives vol. 116,11 (2008): 1568-75. doi: https://doi.org/10.1289/ehp.11516
Woodruff TJ, Zeise L, Axelrad DA, Guyton KZ, Janssen S, Miller M, Miller GG, Schwartz JM, Alexeeff G, Anderson H, Birnbaum L, Bois F, Cogliano VJ, Crofton K, Euling SY, Foster PM, Germolec DR, Gray E, Hattis DB, Kyle AD, Luebke RW, Luster MI, Portier C, Rice DC, Solomon G, Vandenberg J, Zoeller RT. Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making. Environ Health Perspect. 2008 Nov;116(11):1568-75. doi: 10.1289/ehp.11516. Epub 2008 Jul 10. PMID: 19057713; PMCID: PMC2592280.
Copy Download .nbib Format: NLM
New Treatments for Benign Prostatic Hyperplasia: Prostatectomy and other forms of therapy.

Canadian family physician Medecin de famille canadien

Skepasts PK, Lee LM.
PMID: 21229073
Can Fam Physician. 1991 Apr;37:935-9.

Benign prostatic hyperplasia is the most common of all neoplasms. The most common treatment is prostatectomy, but other available therapies include androgen antagonists, α-adrenergic blockers, anticholinergic agents, prostate dilation with a ballon, and urethral stents. Prostatectomy is likely to...

Cite
Skepasts PK, Lee LM. New Treatments for Benign Prostatic Hyperplasia: Prostatectomy and other forms of therapy. Can Fam Physician. 1991;37:935-9
Skepasts, P. K., & Lee, L. M. (1991). New Treatments for Benign Prostatic Hyperplasia: Prostatectomy and other forms of therapy. Canadian family physician Medecin de famille canadien, 37935-9.
Skepasts, P K, and Lee, L M. "New Treatments for Benign Prostatic Hyperplasia: Prostatectomy and other forms of therapy." Canadian family physician Medecin de famille canadien vol. 37 (1991): 935-9.
Skepasts PK, Lee LM. New Treatments for Benign Prostatic Hyperplasia: Prostatectomy and other forms of therapy. Can Fam Physician. 1991 Apr;37:935-9. PMID: 21229073; PMCID: PMC2145650.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 26 entries